2. Disease Areas
  3. Inflammation or Immune System Disease
  4. Allergy

Allergy

Allergy is characterized by an inappropriate immune response to harmless food antigens, with genetic factors playing a significant role through inherited susceptibility variants identified via GWAS and rare monogenic disorders linked to allergic diseases.

References:

 

Allergy (134):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163731
    EGR-1-IN-1 3077196-25-6 99.07%
    EGR-1-IN-1 is a EGR-1 inhibitor with an IC50 of 1.86 μM. EGR-1-IN-1 binds to the zinc finger DNA-binding domain of EGR-1 and promotes the dissociation of the EGR-1-DNA complex. EGR-1-IN-1 reduces the mRNA expression levels of EGR-1-regulated inflammatory genes induced by TNFα. EGR-1-IN-1 alleviates atopic dermatitis-like lesions in the ear skin of mice. EGR-1-IN-1 serves as a lead compound for the development of targeted compounds for inflammatory skin diseases. EGR-1-IN-1 can be used in studies related to atopic dermatitis.
    EGR-1-IN-1
  • HY-P991202
    Anti-TSHR Antibody (M22) 99.46%
    Anti-TSHR Antibody (M22) is a selective agonist targeting TSHR (thyroid-stimulating hormone receptor), acting through competitive binding to the extracellular domain of TSHR. Anti-TSHR Antibody (M22) can mimic the biological effects of thyroid-stimulating hormone (TSH), activating downstream cAMP-PKA and other signaling pathways. Anti-TSHR Antibody (M22) can stimulate the proliferation of thyroid follicular epithelial cells and human umbilical vein endothelial cells (HUVECs), promote angiogenesis and tube formation, cell migration, and also upregulate the expression of angiogenesis-related proteins such as PROX1. Anti-TSHR Antibody (M22) can be used in research areas such as the mechanisms of goiter formation in Graves' disease (GD), angiogenesis regulation, and TSHR antagonist screening.
    Anti-TSHR Antibody (M22)
  • HY-Y0912
    HBTU 94790-37-1 99.80%
    HBTU (N-HBTU) is a guanidinium-based peptide coupling reagent and immunological sensitizer. HBTU can be used in combination with bases such as DIPEA (HY-130142) to complete coupling reactions, with HOBt and TMU as by-products. HBTU is a standard reagent in automated solid-phase peptide synthesis, particularly for the Fmoc/tBu strategy, which effectively promotes coupling steps, but it is not suitable for sterically hindered amino acids or dipeptide derivatives. HBTU can induce rhinitis, dermatitis, bronchial asthma and severe allergic reactions. HBTU can be used to study the pathogenesis of allergic reactions, occupational rhinitis, allergic contact dermatitis and bronchial asthma.
    HBTU
  • HY-B0010
    Formoterol fumarate 43229-80-7 99.95%
    Formoterol fumarate ((±)Formoterol fumarate) is a selective β2-adrenoceptor agonist. Formoterol fumarate is at least as β2-adrenoceptor selective as Salbutamol (HY-B1037) and Terbutaline (HY-B0802A). Formoterol fumarate abolishs the contraction induced by Acetylcholine in bronchioles. Formoterol fumarate can be used for the research of chronic obstructive pulmonary disease and bronchial asthma.
    Formoterol fumarate
  • HY-17360
    Tiotropium Bromide 136310-93-5 99.91%
    Tiotropium bromide (BA-679 BR) is a long-acting anticholinergic bronchodilator. Tiotropium bromide blocks the action of acetylcholine at muscarinic M1, M2, and M3 receptors, prevents bronchoconstriction, and dilates bronchial airways. Tiotropium bromide is applicable to research related to chronic obstructive pulmonary disease and asthma.
    Tiotropium Bromide
  • HY-W140887
    4-Propylguaiacol 2785-87-7 99.95%
    4-Propylguaiacol is a phenolic lignin monomer. 4-Propylguaiacol can be isolated from plants of the Quercus genus. 4-Propylguaiacol can be used in the research of atopic dermatitis.
    4-Propylguaiacol
  • HY-206870
    BP79 3104965-33-2
    BP79 is a potent TSLP receptor inhibitor. BP79 disrupts TSLP-mediated ternary complex formation, blocks TSLPR-IL7Rα co-localization, binds and stabilizes TSLPR, and inhibits phosphorylated STAT3/6. BP79 suppresses immune cell infiltration, secretion of IL-13, IL-4. BP79 can be used for the research of inflammation diseases, such as atopic dermatitis, allergic asthma, and allergic rhinitis.
    BP79
  • HY-Y0823
    Benzoyl isothiocyanate 532-55-8 99.79%
    Benzoyl isothiocyanate is an aromatic isothiocyanate compound found in Sinapis alba L.. Benzoyl isothiocyanate exerts acaricidal activity against Dermatophagoides farina and D. pteronyssinus with LD50 values of 13.8 and 7.63 µg/cm2. Benzoyl isothiocyanate can be used for the research on house dust mite-related allergic disease .
    Benzoyl isothiocyanate
  • HY-76711
    Naltrexone 16590-41-3 99.94%
    Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.
    Naltrexone
  • HY-113166
    Dodecanoylcarnitine 25518-54-1 99.75%
    Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome.
    Dodecanoylcarnitine
  • HY-P990016
    Temtokibart 2639874-57-8 99.23%
    Temtokibart (ARGX-112) is a monoclonal antibody and also an IL-22RA1 inhibitor. Temtokibart inhibits the signal transduction of IL-22, IL-20 and IL-24. Temtokibart reduces the expression levels of inflammatory proteins, chemokines, immune cell migration and markers of activated immune pathways. Temtokibart improves the expression of genes related to immunity and epidermal barrier function. Temtokibart is applicable to research on moderate-to-severe atopic dermatitis.
    Temtokibart
  • HY-125848
    Ginsenoside F2 62025-49-4 99.92%
    Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota. Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma.
    Ginsenoside F2
  • HY-145551
    Atinvicitinib 2169273-59-8 98.62%
    Atinvicitinib is an orally active and selective JAK1 inhibitor. Atinvicitinib blocks signaling of JAK1-dependent pruritogenic and pro-inflammatory cytokines, including those in the IL-31, IL-4, and IL-13 pathways. Atinvicitinib can be used for the researches of pruritus associated with allergic dermatitis and canine atopic dermatitis.
    Atinvicitinib
  • HY-150270A
    NP-1815-PX sodium 1239578-80-3 99.51%
    NP-1815-PX sodium is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC50 of 0.26 μM against human P2X4 receptors. NP-1815-PX sodium specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX sodium selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX sodium not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX sodium exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX sodium is used in studies related to asthma and inflammatory bowel disease (colitis).
    NP-1815-PX sodium
  • HY-N2173
    Forsythoside E 93675-88-8 99.01%
    Forsythoside E is a phenylethanoid glycoside compound. Forsythoside E can be isolated from Shuanghuanglian. Forsythoside E does not induce vascular leakage or promote histamine release in mice. Forsythoside E does not cause pseudo-allergic reactions.
    Forsythoside E
  • HY-132187
    Sphingosylphosphorylcholine 1670-26-4 99.50%
    Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a Kd of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes.
    Sphingosylphosphorylcholine
  • HY-13568
    Benoxaprofen 51234-28-7 99.03%
    Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms.
    Benoxaprofen
  • HY-N3312
    Matairesinol 580-72-3 98.78%
    Matairesinol is an orally active bioactive compound with anti-inflammatory, antioxidant and anticancer activities. Matairesinol inhibits the phosphorylation of MAPK, JNK and NF-κB, downregulates RANKL-induced NFATc1 expression and activity, and suppresses the activation of the PI3K/AKT/FOXO1 pathway. Matairesinol can be used in research related to sepsis-mediated brain injury, osteoporosis, heart failure, atopic dermatitis and cancer.
    Matairesinol
  • HY-P4846
    Ac-Pro-Gly-Pro-OH 292171-04-1 99.49%
    Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a CXCR2 agonist. Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer.
    Ac-Pro-Gly-Pro-OH
  • HY-B0298
    Clemastine 15686-51-8 99.26%
    Clemastine (HS-592; Meclastine) is an orally active, blood-brain barrier-permeable H1 histamine receptor (H1 histamine receptor) antagonist with potent antiallergic effects. Clemastine also antagonizes muscarinic acetylcholine receptors (mAChR), particularly the M1 and M4 subtypes. In addition to antihistamine effects, Clemastine exhibits multiple pharmacological activities, especially in promoting central nervous system remyelination, activating autophagy and pyroptosis, exerting anti-apoptotic and neuroprotective effects, and suppressing inflammation.
    Clemastine